Emerging signaling pathways in hepatocellular carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Signaling pathways are key targets for novel hepatocellular carcinoma (HCC) therapies.
• Sorafenib, a multikinase inhibitor, has shown unprecedented survival benefits in HCC, emphasizing the need to understand signaling networks in cancer cells.
• Numerous signaling modules, including growth factor, cell differentiation, and angiogenesis pathways, are deregulated in HCC.

Purpose of the Study:

• To explore the role of signaling pathways in hepatocellular carcinoma (HCC) development and progression.
• To identify novel therapeutic targets beyond currently explored molecular therapies.
• To investigate the potential of newly identified pathways, such as chromatin remodeling and autophagy, in HCC treatment.

Main Methods:

• Review of signaling pathways implicated in hepatocellular carcinoma (HCC).
• Analysis of molecular mechanisms driving aberrant pathway activation, including mutations and epigenetic changes.
• Leveraging next-generation sequencing to identify novel pathways in HCC research.

Main Results:

• Aberrant activation of growth factor, cell differentiation, and angiogenesis signaling modules is common in HCC.
• Intracellular mediators like RAS and AKT/MTOR are involved in HCC progression.
• Next-generation sequencing has revealed previously underexplored pathways like chromatin remodeling and autophagy in HCC.

Conclusions:

• Understanding complex signaling networks in HCC is essential for therapeutic advancements.
• Novel pathways such as chromatin remodeling and autophagy present potential alternative therapeutic targets for HCC.
• Further investigation into these pathways may overcome limitations of current molecular therapies and improve patient outcomes.